Analyzing...
Loading company...
Titan Biotech Ltd. is a holding company. The company is headquartered in Delhi, Delhi. The firm manufactures peptones, biological extracts, culture media and chemicals. The company offers its products under various categories, such as Food Ingredients, Collagen and Proteins, Pharmaceuticals and Nutraceuticals, Animal Nutrition, Probiotics and Fermentation Ingredients, Agriculture Products, Culture Media and Natures Island. Its Food Ingredients include protein hydrolysate, hydrolyzed vegetable protein (HVP), yeast extract powder, calcium propionate powder, potassium sorbate and calcium lactate. Its Collagen and Proteins include soya protein isolate, calcium caseinate powder, disodium glycine carbonate, essential phospholipids, gluten hydrolysate (wheat) (bacteriological grade) and calcium acetate, among others. Its products are used in the fields of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation and cosmetics, among others.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Chemicals — Specialty & Commodity.”
₹206 Cr revenue.
COGS 46.7%, employees 15.7%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 16.5%▲ | 7.7% |
| ROCE | 20.8%▲ | 10.8% |
| Net Margin | 14.1%▲ | 5.1% |
| EBITDA Margin | 20.8%▲ | 11.1% |
| Debt To Equity | 0.02x▼ | 0.18x |
| Rev Growth 3yr | 13.2%▲ | 2.0% |
| EPS Growth 3yr | 6.3%▲ | -1.3% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹206 Cr +31.8% | ₹156 Cr -4.6% | ₹164 Cr +13.9% | ₹144 Cr -5.8% | ₹153 Cr +7.4% | ₹142 Cr +79.1% | ₹79 Cr +22.4% | ₹65 Cr |
| Other Income | ₹5 Cr +38.3% | ₹4 Cr +123.8% | ₹2 Cr -10.0% | ₹2 Cr +90.1% | ₹1 Cr +29.7% | ₹0.79 Cr +75.4% | ₹0.45 Cr -34.5% | ₹0.69 Cr |
| Total Income | ₹212 Cr +32.0% | ₹160 Cr -3.3% | ₹166 Cr +13.6% | ₹146 Cr -5.1% | ₹154 Cr +7.6% | ₹143 Cr +79.0% | ₹80 Cr +21.8% | ₹66 Cr |
| COGS | ₹96 Cr +32.4% | ₹73 Cr -3.9% | ₹76 Cr +8.2% | ₹70 Cr -6.7% | ₹75 Cr +16.0% | ₹65 Cr +64.1% | ₹39 Cr +20.3% | ₹33 Cr |
| ₹173 Cr +27.5% | ₹136 Cr +1.3% | ₹134 Cr +14.0% | ₹118 Cr +1.9% | ₹116 Cr +15.6% | ₹100 Cr +42.7% | ₹70 Cr +16.7% | ₹60 Cr | |
| Profit Before Tax | ₹38 Cr +56.7% | ₹24 Cr -22.7% | ₹32 Cr +12.1% | ₹28 Cr -26.4% | ₹38 Cr -10.6% | ₹43 Cr +310.5% | ₹10 Cr +87.7% | ₹6 Cr |
| ₹11 Cr +76.0% | ₹6 Cr -22.5% | ₹8 Cr +10.9% | ₹7 Cr -26.5% | ₹10 Cr -12.3% | ₹11 Cr +328.6% | ₹3 Cr +57.3% | ₹2 Cr | |
| Net Profit | ₹30 Cr +38.8% | ₹22 Cr -13.4% | ₹25 Cr +0.0% | ₹25 Cr -13.6% | ₹29 Cr -9.3% | ₹32 Cr +304.5% | ₹8 Cr +100.3% | ₹4 Cr |
| Profit (Owners) | ₹30 Cr +38.8% | ₹22 Cr -13.4% | ₹25 Cr +0.0% | ₹25 Cr -13.6% | ₹29 Cr -9.3% | ₹32 Cr +348.7% | ₹7 Cr +80.6% | ₹4 Cr |
| Other Comprehensive Income | (₹0.09 Cr) ↓ Decline | ₹0.07 Cr -58.2% | ₹0.17 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹0.05 Cr ↑ Recovery | (₹0.05 Cr) ↓ Decline | ₹0.10 Cr |
| EPS | ₹7.23 | ₹5.21 | ₹6.01 | ₹6.01 | ₹6.96 | ₹7.67 | ₹1.71 | ₹0.95 |
| Diluted Shares | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Profit Or Loss Of Associates | ₹2 Cr -25.2% | ₹3 Cr +174.0% | ₹1 Cr -68.8% | ₹4 Cr | ₹0.19 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Newspaper publication of the Audited Financial Results (Standalone & Consolidated) for fourth quarter and year ended March 31, 2026
Intimation for re-appointment of Cost Auditor of the Company
The Board of Director of the Company has recommended a dividend of Rs. 0.50 paisa per Equity Share
Audited Financial Results for March 31, 2026
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. .... Pursua...
Newspaper publication regarding special window for re-lodgement of transfer request and dematerialisation of physical shares.
Annual Secretarial Compliance Report for the financial year ending March 31, 2026
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</...
Newspaper advertisement for Loss of Share Certificate
Closure of Trading Window
Newspaper Publication of the unaudited financial Results (Standalone & Consolidated) for third quarter and nine months ended December, 2025
Unaudited Financial Results (Standalone & Consolidated) for the third quarter and Nine Months Ended December 31, 2025
Outcome of the board meeting held on 12th February, 2026.
Activation of New ISIN for Sub-Division of Equity Shares of the Company.
Corrigendum to Intimation dated 06th February, 2026
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.